Clopidogrel is an antithrombic compound whose active metabolite is a selective, irreversible antagonist of the platelet purinergic P2Y receptor (IC = 100 nM). Clopidogrel inhibits ADP-induced platelet aggregation ex vivo and functions as a prodrug whereupon biotransformation to its active metabolite via CYP2C19 in the liver enables its anti-aggregating activity. Marketed under the name Plavix, clopidogrel in combination with aspirin has been shown to be beneficial in the prevention of vascular ischemic events for patients without deficiencies in CYP2C19-related metabolism.
(±)-Clopidogrel (hydrochloride) is an antithrombotic agent that is ADP-selective and orally available. (±)-Clopidogrel (hydrochloride) inhibits platelet aggregation by inhibiting the binding of ADP to its platelet receptors[1].
IC50&Target
Platelet receptor[1]
分子式
C16H16ClNO2S.HCl
分子量
358.28
CAS号
130209-90-4
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder
-20°C
3 years
4°C
2 years
In solvent
-80°C
6 months
-20°C
1 month
溶解性数据
In Vitro:
DMSO : 50 mg/mL (139.56 mM; ultrasonic and warming and heat to 60°C)